跳至主要内容
临床试验/PER-006-13
PER-006-13未知未知

An Evaluation of the safety, Efficacy and Pharmacokinetics of daptomycin in pediatric subjects aged one to seventeen years with complicated skin and skin structure infections caused by Gram Positive Pathogens.

Cubist Pharmaceuticals, Inc,0 个研究点目标入组 0 人开始时间: 2013年6月11日最近更新:
适应症

试验速览

阶段
未知

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
1 至 2(—)
性别
All

入选标准

  • 1. Written parental (or appropriate legal representative) informed consent prior to any study-related
  • procedure not part of normal medical care;
  • 2. Written subject assent (as appropriate);
  • 3.1 Male or female between the ages of 1 to 17 years old, inclusive;
  • The resto of the information is regsiter in the protocol

排除标准

  • 1. Investigational drug use (including daptomycin) or participation in any experimental procedure in the
  • 30 days preceding study entry;
  • 2. Known allergy/ hypersensitivity to daptomycin;
  • 3. Known infection caused solely by Gram-negative pathogen(s), fungus(i) or virus(es)
  • The resto of the information is regsiter in the protocol

研究者

相似试验